Courtesy of Benzinga.
Biogen (NASDAQ: BIIB) spokesperson says there has been no increase in malignancies in BG-12 clinical trial. No data has been released. Spokesperson says Biopharm Insight had said previously that Biogen’s filings would be delayed and they were not.
For more Benzinga, visit Benzinga Professional Service, Value Investor, and Stocks Under $5.